Rakovina Therapeutics: Transform & Extend the Lives of Patients With Cancer
Developing precision medicines that selectively target and kill cancer cells using leading-edge science to discover and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer
therapeutics from Health Canada, the United States Food and Drug administration and similar international regulatory agencies.
Jeffrey Bacha, BSc, MBA Executive Chairman
Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years as a member of the executive leadership team for multiple companies. Mr. Bacha is the founder and chief executive officer of Edison Oncology Holding Corp., a private corporation that sold assets to establish Rakovina Therapeutics Inc. Prior to founding Edison Oncology, Mr. Bacha co-founded Kintara Therapeutics (NASDAQ: KTRA, formerly DelMar Pharmaceuticals) with Dr. Dennis Brown and served as Chairman and CEO during the company’s growth including the advancement of its lead product candidate to pivotal Phase III clinical trials and NASDAQ listing. Mr. Bacha was served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and as of Vice President, Corporate Development at Inflazyme Corp. Programs advanced by Inimex and Inflazyme have become foundational in Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (NASDAQ: AQXP). He is a member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada. Mr. Bacha currently serves as a consultant to DelMar Pharmaceuticals and Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA). Prior to taking on his operating roles, Mr. Bacha served Senior Manager and Director of KPMG Health Ventures, acting as an advisor to numerous public and private life sciences companies. Mr. Bacha holds an MBA (Hons) from the Goizueta Business School at Emory University (1995) and a degree in BioPhysics from the University of California, San Diego (1991). Mr. Bacha is the inventor or co-inventor on multiple issued U.S. patents and applications, many with foreign counterparts.
For more information on Rakovina Therapeutics Inc. (TSX.V: RKV) please click the investor request info button.